NovaSight develops digital pediatric vision-care products that use AI and eye-tracking technology to diagnose and treat common childhood vision disorders. Its flagship CureSight™ system is an eye-tracking based treatment for amblyopia (lazy eye) that enables cloud monitoring for caregivers and physicians while children watch content at home. The EyeSwift® system is a portable vision-assessment device that screens for multiple vision impairments within seconds. The company plans to use the new funding to advance a large multi-center randomized pivotal study to support FDA 510(k) clearance for its lazy eye treatment device. It also intends to develop future products, including eye-tracking–based active glasses for myopia control. NovaSight is led by CEO Ran Yam and is based in Airport City, Israel; the company has now raised $16M to date.

Total raised

$8M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2020